Elly Gerald Stoica

Array ( [id] => 12904834 [patent_doc_number] => 20180193453 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => TREATMENT-RESISTANCE REDUCING AGENT FOR TREATMENT-RESISTANT CANCER [patent_app_type] => utility [patent_app_number] => 15/736203 [patent_app_country] => US [patent_app_date] => 2016-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4493 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15736203 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15239685 [patent_doc_number] => 20190374628 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => MUTATED FRAGMENTS OF THE RAS PROTEIN [patent_app_type] => utility [patent_app_number] => 15/736472 [patent_app_country] => US [patent_app_date] => 2016-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29920 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15736472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13761217 [patent_doc_number] => 10172937 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-08 [patent_title] => Method of treatment of malignant solid tumors with afucosylated anti-FGFR2IIIb antibodies [patent_app_type] => utility [patent_app_number] => 15/166798 [patent_app_country] => US [patent_app_date] => 2016-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 26 [patent_no_of_words] => 23658 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15166798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14960743 [patent_doc_number] => 20190307849 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-10 [patent_title] => METHODS OF USING INTERLEUKIN-10 FOR TREATING DISEASES AND DISORDERS [patent_app_type] => utility [patent_app_number] => 15/576239 [patent_app_country] => US [patent_app_date] => 2016-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28621 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15576239 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11335660 [patent_doc_number] => 20160361415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-15 [patent_title] => 'Methods of Using Interleukin-10 for Treating Diseases and Disorders' [patent_app_type] => utility [patent_app_number] => 15/165918 [patent_app_country] => US [patent_app_date] => 2016-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 29759 [patent_no_of_claims] => 67 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15165918 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11381618 [patent_doc_number] => 20170007673 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-12 [patent_title] => 'THERAPEUTIC AGENT FOR RHINITIS' [patent_app_type] => utility [patent_app_number] => 15/160268 [patent_app_country] => US [patent_app_date] => 2016-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 22146 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15160268 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12942667 [patent_doc_number] => 09833514 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-12-05 [patent_title] => Use of pegylated IL-10 to treat cancer [patent_app_type] => utility [patent_app_number] => 15/155770 [patent_app_country] => US [patent_app_date] => 2016-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10873 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15155770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11047541 [patent_doc_number] => 20160244500 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-25 [patent_title] => 'NATRIURETIC POLYPEPTIDES WITH UNIQUE PHARMACOLOGIC PROFILES' [patent_app_type] => utility [patent_app_number] => 15/153955 [patent_app_country] => US [patent_app_date] => 2016-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 11382 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15153955 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12566577 [patent_doc_number] => 10017768 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-10 [patent_title] => Method of treatment of chlamydial infections with selected EGFR inhibitors [patent_app_type] => utility [patent_app_number] => 15/153401 [patent_app_country] => US [patent_app_date] => 2016-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 33 [patent_no_of_words] => 19623 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15153401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15306503 [patent_doc_number] => 10517933 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-31 [patent_title] => Method of treating androgen receptor negative prostate tumors and their metastases [patent_app_type] => utility [patent_app_number] => 15/566031 [patent_app_country] => US [patent_app_date] => 2016-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 44 [patent_no_of_words] => 21414 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15566031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11581780 [patent_doc_number] => 09636400 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-02 [patent_title] => 'VEGF specific fusion protein antagonist formulations' [patent_app_type] => utility [patent_app_number] => 15/150840 [patent_app_country] => US [patent_app_date] => 2016-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5661 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15150840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14852197 [patent_doc_number] => 10414810 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-09-17 [patent_title] => Double mutant survivin vaccine [patent_app_type] => utility [patent_app_number] => 15/568967 [patent_app_country] => US [patent_app_date] => 2016-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 39 [patent_no_of_words] => 32747 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15568967 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11053331 [patent_doc_number] => 20160250293 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-01 [patent_title] => 'COMPOSITION FOR EXTERNAL PREPARATION FOR SKIN' [patent_app_type] => utility [patent_app_number] => 15/148470 [patent_app_country] => US [patent_app_date] => 2016-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 38510 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15148470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11888030 [patent_doc_number] => 09758582 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-09-12 [patent_title] => 'Anti-CTLA4 antibody-TGF-βRII targeted/immunomodulatory fusion proteins' [patent_app_type] => utility [patent_app_number] => 15/145135 [patent_app_country] => US [patent_app_date] => 2016-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 65 [patent_figures_cnt] => 65 [patent_no_of_words] => 13956 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15145135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11031592 [patent_doc_number] => 20160228546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-11 [patent_title] => 'MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING THEREOF' [patent_app_type] => utility [patent_app_number] => 15/140944 [patent_app_country] => US [patent_app_date] => 2016-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 50985 [patent_no_of_claims] => 234 [patent_no_of_ind_claims] => 44 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15140944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11099642 [patent_doc_number] => 20160296611 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-13 [patent_title] => 'Controlled Delivery of TLR Agonists in Structural Polymeric Devices' [patent_app_type] => utility [patent_app_number] => 15/135216 [patent_app_country] => US [patent_app_date] => 2016-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 47147 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15135216 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11023713 [patent_doc_number] => 20160220668 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-04 [patent_title] => 'Continuous Cell Programming Devices' [patent_app_type] => utility [patent_app_number] => 15/135294 [patent_app_country] => US [patent_app_date] => 2016-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 26284 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15135294 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14482749 [patent_doc_number] => 10328135 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-25 [patent_title] => Method of obtaining cytolytic T cells by using mutant tumor epitopes [patent_app_type] => utility [patent_app_number] => 15/098274 [patent_app_country] => US [patent_app_date] => 2016-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 10 [patent_no_of_words] => 8841 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15098274 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12580929 [patent_doc_number] => 20180085472 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => COMBINATION THERAPY FOR CANCER [patent_app_type] => utility [patent_app_number] => 15/564866 [patent_app_country] => US [patent_app_date] => 2016-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25079 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15564866 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15483247 [patent_doc_number] => 10556956 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-11 [patent_title] => Pharmaceutical compositions comprising humanized anti-CCR4 IgG4 antibody [patent_app_type] => utility [patent_app_number] => 15/571202 [patent_app_country] => US [patent_app_date] => 2016-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 19 [patent_no_of_words] => 19619 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 137 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15571202 [rel_patent_id] =>[rel_patent_doc_number] =>)